替诺福韦酯单药治疗慢性乙型肝炎的临床效果

替诺福韦酯单药治疗慢性乙型肝炎的临床效果
Abstract: Objective: To investigate the safety and efficacy of tenofovir alafenamide in the treatment of chronic hepatitis B (CP-A, B, and C stages).Methods: Sixty patients with CP-A, B, and C chronic hepatitis B were randomly divided into two groups. Thirty patients in the treatment group were treated with tenofovir alafenamide alone, and 30 patients in the control group were treated with lamivudine alone. Both groups were administered orally for 48 weeks, and were followed up for 12 weeks after treatment. The clinical efficacy, changes in transaminase and viral antigen expression in the two groups of patients were evaluated and the incidence of adverse reactions were compared. Results: The ALT, AST and viral antigen expression in the treatment group were significantly lower than those in the control group (P <0.05); the total effective rate of the treatment group was 93.3%, and that of the control group was 86.7%, with no significant difference between the two groups. (P ＞ 0.05). There was no significant difference in adverse reactions such as low white blood cells, low platelets, and liver damage between the treatment group and the control group (P> 0.05). Conclusion: Tenofovir alafenamide monotherapy for chronic hepatitis B (CP-A, B, and C stages) is safe and effective and can be used as an effective clinical treatment drug.
Keywords：Tenofovir alafenamide; chronic hepatitis B; monotherapy; clinical efficacy; safety。